The burgeoning landscape of therapeutic interventions for obesity disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While https://harleyyyvx233246.atualblog.com/45623200/glp-3-retatrutide-a-comparative-analysis